BIOLOGICS FEATURED ARTICLES
First-In-Human Trials: A Make-Or-Break Milestone For Small Biopharmas
Whether biopharmaceutical companies have one candidate or 100, the directive is clear: moving quickly into FIH testing is essential. But, how?
Challenges, Risks And Strategies For Biologic Substance Manufacturing
From discussions with pharmaceutical and biotechnology industry leaders, it is clear that demand forecasting is a significant challenge when planning biologic drug substance production.
The Right Biomanufacturing Partner Can Mitigate Forecasting Risks
While forecasts can never be 100-percent accurate, the goal for biopharmaceutical forecasters should be to minimize the degree of inaccuracies as much as possible.
Top 5 Risks Facing Your Small Biopharma Clients Today
For small biopharma innovators, steep development costs are compounded by the fact that large molecules are becoming increasingly complex and present serious clinical or manufacturing problems.
Targeted Therapies Drive Need For Flexible, Small-Volume Manufacturing
Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies.
Implications Of Inaccurate Forecasting On Biologics Manufacturing
Inaccurate demand forecasts can have significant implications for companies developing biologics. And, it is increasingly difficult to locate capacity to respond to demand changes.
Inaccurate Forecasting Is Here To Stay: Focus On Managing Risk Instead
It’s no secret that drug forecasts are notoriously incorrect, and often by large margins. With no signs of improvement in forecasting accuracy, how do companies minimize risk?
Thermo Fisher Scientific
4721 Emperor Blvd., Suite 200
Durham, NC 27703-8580
Phone: +1 919 226 3200